These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28826693)

  • 1. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
    Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
    Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The what, when and how of CAR T cell therapy for ALL.
    Frey N
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.
    Ramos CA; Savoldo B; Torrano V; Ballard B; Zhang H; Dakhova O; Liu E; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Brenner MK; Heslop HE; Dotti G
    J Clin Invest; 2016 Jul; 126(7):2588-96. PubMed ID: 27270177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
    Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
    Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.
    Frey NV; Gill S; Hexner EO; Schuster S; Nasta S; Loren A; Svoboda J; Stadtmauer E; Landsburg DJ; Mato A; Levine BL; Lacey SF; Melenhorst JJ; Veloso E; Gaymon A; Pequignot E; Shan X; Hwang WT; June CH; Porter DL
    J Clin Oncol; 2020 Sep; 38(25):2862-2871. PubMed ID: 32298202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
    Mancikova V; Smida M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
    Li X; Chen W
    Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.